Cargando…

Ipilimumab in a Phase II trial of melanoma patients with brain metastases

In a Phase II clinical study enrolling individuals with melanoma brain metastases, 51 asymptomatic patients (cohort A) and 21 on a stable steroid dose (cohort B) received 4 courses of 10 mg/kg intravenous ipilimumab (induction), then (at 24 weeks) maintenance therapy with the same dose of ipilimumab...

Descripción completa

Detalles Bibliográficos
Autor principal:	Margolin, Kim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2012
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494644/ https://www.ncbi.nlm.nih.gov/pubmed/23170278 http://dx.doi.org/10.4161/onci.20687

Ejemplares similares

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
por: Grimaldi, Antonio M, et al.
Publicado: (2014)

Melanoma metastases caught in the AKT
por: Kircher, David A., et al.
Publicado: (2016)

Location, location, location: The relationship of anatomic site, antigen expression, and T-cell infiltration in human melanoma metastases
por: Bartlett, Edmund K, et al.
Publicado: (2014)

Ipilimumab and radiation therapy for melanoma brain metastases
por: Silk, Ann W, et al.
Publicado: (2013)

Is there a future for adoptive cell transfer in melanoma patients?
por: Besser, Michal J
Publicado: (2013)

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
por: Queirolo, Paola, et al.
Publicado: (2014)

The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions
por: Pagès, Franck, et al.
Publicado: (2020)

The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions
por: Lanzi, Anastasia, et al.
Publicado: (2020)

Melanoma immunoediting by NK cells
por: Balsamo, Mirna, et al.
Publicado: (2012)

Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches
por: Maurer, Margarita, et al.
Publicado: (2012)

Identification of new prognostic biomarkers for Stage III metastatic melanoma patients
por: Kakavand, Hojabr, et al.
Publicado: (2013)

Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery
por: Tazi, Karim, et al.
Publicado: (2015)

How melanoma cells inactivate NK cells
por: Pietra, Gabriella, et al.
Publicado: (2012)

BRAF-targeted therapy and immune responses to melanoma
por: Ngiow, Shin Foong, et al.
Publicado: (2013)

Disseminating melanoma cells surf on calcium waves
por: Sun, Jianwei, et al.
Publicado: (2015)

Forging a link between oncogenic signaling and immunosuppression in melanoma
por: Khalili, Jahan S., et al.
Publicado: (2013)

NRAS-driven melanoma: A RAF can hide another
por: Druillennec, Sabine, et al.
Publicado: (2017)

Preventing surgery-induced NK cell dysfunction and cancer metastases with influenza vaccination
por: Tai, Lee-Hwa, et al.
Publicado: (2013)

The antigen specific composition of melanoma tumor infiltrating lymphocytes?
por: Hadrup, Sine Reker
Publicado: (2012)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

Lymphoid neogenesis in melanoma: What does it tell us?
por: van Baren, Nicolas, et al.
Publicado: (2013)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Engineering hematopoietic stem cells to create melanoma specific CTL
por: Vatakis, Dimitrios
Publicado: (2012)

Neuropilin 1 guides regulatory T cells into VEGF-producing melanoma
por: Hansen, Wiebke
Publicado: (2013)

A path from melanocyte stem cells to cutaneous melanoma illuminated by UVB
por: Moon, Hyeongsun, et al.
Publicado: (2018)

“Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy
por: Janji, Bassam, et al.
Publicado: (2021)

A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain
por: Ruzevick, Jacob, et al.
Publicado: (2013)

New strategies for melanoma immunotherapy: How to overcome immunosuppression in the tumor microenvironment
por: Umansky, Viktor
Publicado: (2012)

Enhancing anti-melanoma immunity by electrochemotherapy and in vivo dendritic-cell activation
por: Gerlini, Gianni, et al.
Publicado: (2012)

Immune response markers in sentinel nodes may predict melanoma progression
por: Rodolfo, Monica, et al.
Publicado: (2014)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013)

Melanoma hijacks plasmacytoid dendritic cells to promote its own progression
por: Aspord, Caroline, et al.
Publicado: (2014)

Counteracting oxidative phosphorylation-mediated resistance of melanomas to MAPK pathway inhibition
por: McQuade, Jennifer L, et al.
Publicado: (2015)

Type 2 innate lymphoid cells: a novel actor in anti-melanoma immunity
por: Jacquelot, Nicolas, et al.
Publicado: (2021)

Acute motor axonal neuropathy after ipilimumab and nivolumab treatment in melanoma brain metastases: A case report and review of the literature
por: Piña, Yolanda, et al.
Publicado: (2021)

KMT2D deficiency confers a therapeutic vulnerability to glycolytic and IGFR inhibitors in melanoma
por: Murugesan, Navya, et al.
Publicado: (2021)

Monocytic myeloid-derived suppressor cells in advanced melanoma patients: Indirect impact on prognosis through inhibition of tumor-specific T-cell responses?
por: Martens, Alexander, et al.
Publicado: (2014)

When unity makes strength: Combinatorial NK cell-based immunotherapies against melanoma
por: Messaoudene, Meriem, et al.
Publicado: (2014)

The extent to which melanoma alters tissue-resident dendritic cell function correlates with tumorigenicity
por: Hargadon, Kristian Michael
Publicado: (2015)

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_i4ovh18tvm4lnh2mr403vgtp9n